Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

By sjmartinez • January 25, 2025

Krishnan S, Srivastava PK, Attaluri J, Nayeri R, Chatterjee D, Patel J, Nsair A, Budoff M, Nayeri A. Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence. J Cardiovasc Dev Dis. 2025 Jan 7;12(1):19. doi: 10.3390/jcdd12010019. PMID: 39852297; PMCID: PMC11766028.

Tags: Cardiology/Epi, GIP GLP-1 receptor agonist, Harbor UCLA, Hematology/Oncology, Metabolic syndrome, Obesity, Publications, semaglutide, tirzepatide, Veterans Administration, weight loss

Mechanomedicine

Liu Z, Chen G, Jo MS, Vogel V, Chen J, Rogers JA, Li S. Mechanomedicine. Nat Rev Bioeng. 2026 Mar;4(3):216-235. doi: 10.1038/s44222-025-00391-6. Epub 2026 Jan[...]

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis

Umbleja T, Zafar MU, McCallum S, Gattu AK, Zanni MV, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Currier JS, Sponseller CA, Diggs MR, Chu SM, Lu[...]

Trends and Disparities in Aortic Stenosis and Coronary Artery Disease-Related Mortality Among U.S. Adults Aged ≥65 Years, 1999-2024

Daniyal SM, Sarwar M, Fahim SL, Khatoon NM, Noor A, Batool F, Riaz M, Ajaz H, Gondal HT, Aftab Z, Gul I, Fonarow GC. Trends[...]